BioSpace News Archive

Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced new preclinical data from our CDK12 inhibitor program, demonstrating robust anti-tumor activity of our oral, selective CDK12 inhibitors in models of breast, lung, and ovarian cancer, including in a PARP inhibitor resistant model.

Immunomic Therapeutics, Inc., (“ITI”), a privately-held clinical-stage biotechnology company pioneering the study of LAMP-mediated nucleic acid-based immunotherapy, announced today that the data from two posters are being presented at the American Association for Cancer Research (AACR) Annual Meeting 2022 held in New Orleans, Louisiana, from April 8-13.

Nuvalent, Inc., (Nasdaq: NUVL) a clinical-stage biopharmaceutical company creating precisely targeted therapies for patients with cancer, today announced new data to support broad clinical exploration of its parallel lead programs NVL-520 – a ROS1-selective inhibitor – and NVL-655 – an ALK-selective inhibitor.

OncoMyx Therapeutics, a privately-held oncolytic virus immunotherapy company, today announced the presentation of new preclinical data at the American Association for Cancer Research (AACR) Annual Meeting 2022 being held April 8-13.

Researchers at City of Hope, one of the largest cancer research and treatment organizations in the United States, will present late-breaking and clinical trial findings at this year’s American Association for Cancer Research Annual Meeting, which begins today.

MEI Pharma, Inc. (NASDAQ: MEIP), today announced that two posters presenting preclinical data will be presented at the American Association for Cancer Research (AACR) Annual Meeting 2022 for zandelisib, an orally administered phosphatidylinositol-3-kinase (PI3K) inhibitor, and ME-344, a tumor selective mitochondrial inhibitor.

Palleon Pharmaceuticals, a company pioneering the field of glyco-immunology to treat cancer and inflammatory diseases, today presented new preclinical data on the company’s lead oncology program, E-602, as well as data supporting Palleon’s novel bifunctional PD-L1-Targeted Sialidase, in two poster presentations at the American Association for Cancer Research Annual Meeting in New Orleans, La.

Nimbus Therapeutics, a clinical-stage company that designs and develops breakthrough medicines through its powerful computational drug discovery engine, is sharing preclinical data, released today, on its Casitas B-lineage lymphoma b (Cbl-b) inhibitor, NTX-801, at the American Association for Cancer Research (AACR) 2022 Annual Meeting, being held April 8-13, 2022, in New Orleans, LA.

Orum Therapeutics, a private biotechnology company pioneering the development of tumor-directed targeted protein degraders (TPDs), today presented preclinical data for ORM-5029, a potential first-in-class TPD therapy for HER2-positive cancers, at the American Association for Cancer Research (“AACR”) Annual Meeting 2022.

OncoOne, a biotechnology company focused on discovering precision medicines for cancer and autoimmune diseases, announced today the presentation of preclinical proof-of-concept data on its lead candidate ON203, a therapeutic monoclonal antibody targeting oxMIF, and the radiodiagnostic 89Zr-ON102, at the American Association for Cancer Research (AACR) Annual Meeting 2022, held from April 8-13, in New Orleans, Louisiana.